Skip to main content
Top
Published in: Arthritis Research & Therapy 2/2011

01-04-2011 | Editorial

What do measurements of molecular biomarkers in different body fluids really tell us?

Author: A Robin Poole

Published in: Arthritis Research & Therapy | Issue 2/2011

Login to get access

Abstract

Molecular or biochemical biomarkers of joint metabolism offer promise in helping us understand joint pathology, its detection and treatment. But they have often been studied alone and in only one body fluid. Although the synovial joint is usually the focus of most arthritis pathology, it is often difficult, for a variety of reasons, to obtain synovial fluid that should best reflect changes in biomarkers related to pathology. It is therefore very important to see whether analyses of more readily obtainable sera and urine also reflect changes in synovial fluid. Catterall and colleagues, in a paper in Arthritis Research & Therapy that examines very early biomarker changes following joint injury, provide us with some insights into these important questions. As the study was very small and examined very early changes following joint injury, prior to onset of any recognisable pathology, we look forward to future larger biomarker studies of this kind in patients with clinically defined arthritic changes to which we can relate biomarker data.
Literature
1.
go back to reference Catterall JB, Stabler TS, Flannery CR, Kraus VB: Changes in serum and synovial fluid biomarkers after acute injury. Arthritis Res Ther. 2010, 12: R229-10.1186/ar3216.PubMedCentralCrossRefPubMed Catterall JB, Stabler TS, Flannery CR, Kraus VB: Changes in serum and synovial fluid biomarkers after acute injury. Arthritis Res Ther. 2010, 12: R229-10.1186/ar3216.PubMedCentralCrossRefPubMed
2.
go back to reference Poole AR, Blake S, Buschmann M, Goldring S, Laverty S, Lockwood S, Matyas J, McDougall J, Pritzker K, Rudolphi K, van den Berg W, Yaksh T: Recommendations for the use of preclinical models in the study and treatment of osteoarthritis. Osteoarthritis Cartilage. 2010, 18: S10-S16.CrossRefPubMed Poole AR, Blake S, Buschmann M, Goldring S, Laverty S, Lockwood S, Matyas J, McDougall J, Pritzker K, Rudolphi K, van den Berg W, Yaksh T: Recommendations for the use of preclinical models in the study and treatment of osteoarthritis. Osteoarthritis Cartilage. 2010, 18: S10-S16.CrossRefPubMed
3.
go back to reference Cibere J, Zhang H, Garnero P, Poole AR, Lobanok T, King L, Saxne T, Kraus VB, Way A, Thorne A, Wong H, Singer J, Kopec J, Guermazi A, Peterfy C, Nicolaou C, Munk P, Esdaile JM: Association of biomarkers with pre-radiographically defined an radiographically defined knee osteoarthritis in a populationbased cohort. Arthritis Rheum. 2009, 60: 1372-1380. 10.1002/art.24473.CrossRefPubMed Cibere J, Zhang H, Garnero P, Poole AR, Lobanok T, King L, Saxne T, Kraus VB, Way A, Thorne A, Wong H, Singer J, Kopec J, Guermazi A, Peterfy C, Nicolaou C, Munk P, Esdaile JM: Association of biomarkers with pre-radiographically defined an radiographically defined knee osteoarthritis in a populationbased cohort. Arthritis Rheum. 2009, 60: 1372-1380. 10.1002/art.24473.CrossRefPubMed
4.
go back to reference Bay-Jensen AC, Andersen TL, Charni-Ben Tabassi N, Kristensen PW, Kjaersgaard-Andersen P, Sandell L, Garnero P, Delaisse JM: Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage. Osteoarthritis Cartilage. 2008, 16: 615-623. 10.1016/j.joca.2007.09.006.CrossRefPubMed Bay-Jensen AC, Andersen TL, Charni-Ben Tabassi N, Kristensen PW, Kjaersgaard-Andersen P, Sandell L, Garnero P, Delaisse JM: Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage. Osteoarthritis Cartilage. 2008, 16: 615-623. 10.1016/j.joca.2007.09.006.CrossRefPubMed
5.
go back to reference Cahue S, Sharma L, Dunlop D, Ionescu M, Song J, Lobanok T, King L, Poole AR: The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. Osteoarthritis Cartilage. 2007, 15: 819-823. 10.1016/j.joca.2007.01.016.PubMedCentralCrossRefPubMed Cahue S, Sharma L, Dunlop D, Ionescu M, Song J, Lobanok T, King L, Poole AR: The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. Osteoarthritis Cartilage. 2007, 15: 819-823. 10.1016/j.joca.2007.01.016.PubMedCentralCrossRefPubMed
6.
go back to reference Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, Delmas PD: Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum. 2002, 46: 2613-2624. 10.1002/art.10576.CrossRefPubMed Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, Delmas PD: Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum. 2002, 46: 2613-2624. 10.1002/art.10576.CrossRefPubMed
7.
go back to reference Kraus VB, Huebner JL, Fink C, King JB, Brown S, Vail TP, Guilak F: Urea as a passive transport marker for arthritis biomarker studies. Arthritis Rheum. 2002, 46: 420-427. 10.1002/art.10124.CrossRefPubMed Kraus VB, Huebner JL, Fink C, King JB, Brown S, Vail TP, Guilak F: Urea as a passive transport marker for arthritis biomarker studies. Arthritis Rheum. 2002, 46: 420-427. 10.1002/art.10124.CrossRefPubMed
Metadata
Title
What do measurements of molecular biomarkers in different body fluids really tell us?
Author
A Robin Poole
Publication date
01-04-2011
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 2/2011
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3276

Other articles of this Issue 2/2011

Arthritis Research & Therapy 2/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.